12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights 1 hour ago
Movers
Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS) stock
Gainers
- Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million.
- Fractyl Health (NASDAQ:GUTS) stock moved upwards by 5.89% to $0.95. The company's market cap stands at $12.3 million.
- Ovid Therapeutics (NASDAQ:OVID) stock moved upwards by 5.26% to $3.0. The company's market cap stands at $556.5 million.
- ARS Pharmaceuticals (NASDAQ:SPRY) stock increased by 3.17% to $3.25. The market value of their outstanding shares is at $280.4 million. As per the press release, Q3 earnings came out 2 days ago.
- Altimmune (NASDAQ:ALT) shares moved upwards by 2.99% to $2.18. The company's market cap stands at $404.5 million.
- CEL-SCI (AMEX:CVM) shares rose 2.96% to $1.39. The company's market cap stands at $25.5 million.
Losers
- Tvardi Therapeutics (NASDAQ:TVRD) shares declined by 8.5% to $1.29 during Monday's after-market session. The company's market cap stands at $12.7 million.
- Acadia Pharmaceuticals (NASDAQ:ACAD) shares decreased by 7.28% to $15.3. The market value of their outstanding shares is at $3.6 billion. The company's, Q3 earnings came out 3 days ago.
- Estrella Immunopharma (NASDAQ:ESLA) stock fell 5.24% to $0.49. The company's market cap stands at $16.3 million.
- Obsidian Therapeutics (NASDAQ:OBX) shares decreased by 5.18% to $13.0. The market value of their outstanding shares is at $856.4 million.
- ALX Oncology Holdings (NASDAQ:ALXO) stock fell 5.06% to $1.22. The market value of their outstanding shares is at $155.4 million.
- Optimi Health (NASDAQ:OPTH) stock decreased by 4.63% to $2.38. The market value of their outstanding shares is at $13.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
